The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration. Predicted molecular weight: 43 kDa.
Is unsuitable for Flow Cyt,ICC/IF,IHC-P or IP.
Catalyzes the conversion of dihydroorotate to orotate with quinone as electron acceptor.
Pyrimidine metabolism; UMP biosynthesis via de novo pathway; orotate from (S)-dihydroorotate (quinone route): step 1/1.
Involvement in disease
Defects in DHODH are the cause of postaxial acrofacial dysostosis (POADS) [MIM:263750]; also known as Miller syndrome. POADS is characterized by severe micrognathia, cleft lip and/or palate, hypoplasia or aplasia of the posterior elements of the limbs, coloboma of the eyelids and supernumerary nipples. POADS is a very rare disorder: only 2 multiplex families, each consisting of 2 affected siblings born to unaffected, nonconsanguineous parents, have been described among a total of around 30 reported cases.
Belongs to the dihydroorotate dehydrogenase family. Type 2 subfamily.
The uncleaved transit peptide is required for mitochondrial targeting and proper membrane integration.